We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Certara (CERT) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Certara, Inc. (CERT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Certara, Inc. is one of 1167 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Certara, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CERT's full-year earnings has moved 5.8% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that CERT has returned about 26.5% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -6.6% on a year-to-date basis. This means that Certara, Inc. is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Compugen (CGEN - Free Report) . The stock is up 2% year-to-date.
For Compugen, the consensus EPS estimate for the current year has increased 23.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Certara, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 553 individual companies and currently sits at #99 in the Zacks Industry Rank. This group has lost an average of 6.8% so far this year, so CERT is performing better in this area. Compugen is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Certara, Inc. and Compugen. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Certara (CERT) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Certara, Inc. (CERT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Certara, Inc. is one of 1167 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Certara, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CERT's full-year earnings has moved 5.8% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that CERT has returned about 26.5% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -6.6% on a year-to-date basis. This means that Certara, Inc. is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Compugen (CGEN - Free Report) . The stock is up 2% year-to-date.
For Compugen, the consensus EPS estimate for the current year has increased 23.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Certara, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 553 individual companies and currently sits at #99 in the Zacks Industry Rank. This group has lost an average of 6.8% so far this year, so CERT is performing better in this area. Compugen is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Certara, Inc. and Compugen. These stocks will be looking to continue their solid performance.